{ "format" : "linked-data-api", "version" : "0.2", "result" : {"_about" : "http://eldaddp.azurewebsites.net/answeredquestions.text?min-answer.dateOfAnswer=2014-10-28&min-answer.questionFirstMinisteriallyCorrected.=2014-11-13T10%3A22%3A56.0372213Z&answer.answeringMemberConstituency=Mid+Norfolk", "definition" : "http://eldaddp.azurewebsites.net/meta/answeredquestions.text?min-answer.dateOfAnswer=2014-10-28&min-answer.questionFirstMinisteriallyCorrected.=2014-11-13T10%3A22%3A56.0372213Z&answer.answeringMemberConstituency=Mid+Norfolk", "extendedMetadataVersion" : "http://eldaddp.azurewebsites.net/answeredquestions.text?min-answer.dateOfAnswer=2014-10-28&min-answer.questionFirstMinisteriallyCorrected.=2014-11-13T10%3A22%3A56.0372213Z&answer.answeringMemberConstituency=Mid+Norfolk&_metadata=all", "first" : "http://eldaddp.azurewebsites.net/answeredquestions.text?min-answer.dateOfAnswer=2014-10-28&_page=0&min-answer.questionFirstMinisteriallyCorrected.=2014-11-13T10%3A22%3A56.0372213Z&answer.answeringMemberConstituency=Mid+Norfolk", "hasPart" : "http://eldaddp.azurewebsites.net/answeredquestions.text?min-answer.dateOfAnswer=2014-10-28&min-answer.questionFirstMinisteriallyCorrected.=2014-11-13T10%3A22%3A56.0372213Z&answer.answeringMemberConstituency=Mid+Norfolk", "isPartOf" : "http://eldaddp.azurewebsites.net/answeredquestions.text?min-answer.dateOfAnswer=2014-10-28&min-answer.questionFirstMinisteriallyCorrected.=2014-11-13T10%3A22%3A56.0372213Z&answer.answeringMemberConstituency=Mid+Norfolk", "items" : [{"_about" : "http://data.parliament.uk/resources/1146644", "AnsweringBody" : [{"_value" : "Department for Transport"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1146644/answer", "answerText" : {"_value" : "

Since 1 January 2019, the Department has liaised with Suffolk County Council to support them in developing the evidence required to facilitate a thorough and efficient assessment of the proposed scheme. This has included analytical support to scheme promoters, in advance of Transport East submitting the scheme proposal to the Department on the County Council\u2019s behalf in July 2019, and following this submission.<\/del><\/p>

Department for Transport officials have had regular discussions with Suffolk County Council regarding the Ipswich Northern Route since January 1 2019. As well as regular engagement, the Department has offered analytical support to all scheme promoters as part of the Major Road Network (MRN) and Large Local Majors (LLM) programme.<\/ins><\/p>

<\/p>

<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4020", "label" : {"_value" : "Biography information for George Freeman"} } , "answeringMemberConstituency" : {"_value" : "Mid Norfolk"} , "answeringMemberPrinted" : {"_value" : "George Freeman"} , "dateOfAnswer" : {"_value" : "2019-10-01", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "true", "_datatype" : "boolean"} , "previousAnswerVersion" : {"_about" : "http://data.parliament.uk/resources/1146644/answer/previousversion/136591", "answeringMember" : {"_about" : "http://data.parliament.uk/members/4020", "label" : {"_value" : "Biography information for George Freeman"} } , "answeringMemberConstituency" : {"_value" : "Mid Norfolk"} , "answeringMemberPrinted" : {"_value" : "George Freeman"} } , "questionFirstAnswered" : [{"_value" : "2019-10-01T16:04:51.793Z", "_datatype" : "dateTime"} ], "questionFirstMinisteriallyCorrected" : [{"_value" : "2019-10-08T13:22:47.04Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "27"} , "answeringDeptShortName" : {"_value" : "Transport"} , "answeringDeptSortName" : {"_value" : "Transport"} , "date" : {"_value" : "2019-09-26", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Roads: Suffolk"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Transport, what discussions his Department has had with Suffolk county council on the Ipswich northern route since 1 January 2019.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4678", "label" : {"_value" : "Biography information for Sandy Martin"} } , "tablingMemberConstituency" : {"_value" : "Ipswich"} , "tablingMemberPrinted" : [{"_value" : "Sandy Martin"} ], "uin" : "291481"} , {"_about" : "http://data.parliament.uk/resources/522126", "AnsweringBody" : [{"_value" : "Department of Health"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/522126/answer", "answerText" : {"_value" : "

There are two<\/del> three <\/ins>human papilloma virus vaccines licensed in the European Union: Cervarix,<\/ins> and<\/del> Gardasil and <\/ins>Gardasil 9. These products are licensed centrally throughout Europe by the European Commission via the European Medicines Agency (EMA). Applicants for centrally authorised products are required to submit all relevant supporting clinical trials data, whether published or not, to the EMA directly and not to the Medicines and Healthcare products Regulatory Agency.<\/p>

<\/p>

Under current medicines legislation, the EMA database registers all EU-approved clinical trials of investigational medicinal products. Since March 2011 this information has been publicly accessible through the EU Clinical Trials Register (except adult Phase 1 trials). The EU Clinical Trials Register includes all EU-conducted trials since May 2004 when the Clinical Trials Directive was implemented and can be found here:<\/p>

<\/p>

https://www.clinicaltrialsregister.eu/ctr-search/search<\/a><\/p>

<\/p>

Furthermore since July 2014 clinical trial sponsors have been required to provide a summary of their trial results uploaded onto the EU Clinical Trials Register within one year of their trial completing. There is a two year programme of back-loading underway to provide summaries of trial results for all trials on the Register back to when the EudraCT database was initiated in May 2004.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4020", "label" : {"_value" : "Biography information for George Freeman"} } , "answeringMemberConstituency" : {"_value" : "Mid Norfolk"} , "answeringMemberPrinted" : {"_value" : "George Freeman"} , "dateOfAnswer" : {"_value" : "2016-06-07", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "true", "_datatype" : "boolean"} , "previousAnswerVersion" : {"_about" : "http://data.parliament.uk/resources/522126/answer/previousversion/2228", "answeringMember" : {"_about" : "http://data.parliament.uk/members/4020", "label" : {"_value" : "Biography information for George Freeman"} } , "answeringMemberConstituency" : {"_value" : "Mid Norfolk"} , "answeringMemberPrinted" : {"_value" : "George Freeman"} } , "questionFirstAnswered" : [{"_value" : "2016-06-07T10:57:37.313Z", "_datatype" : "dateTime"} ], "questionFirstMinisteriallyCorrected" : [{"_value" : "2016-06-13T10:14:27.603Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health"} , "answeringDeptSortName" : {"_value" : "Health"} , "date" : {"_value" : "2016-05-26", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Human Papillomavirus: Vaccination"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Health, whether the Medicines and Healthcare Products Regulatory Agency holds any clinical trial data for HPV vaccines which is not in the public domain.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/1506", "label" : {"_value" : "Biography information for Andrew Gwynne"} } , "tablingMemberConstituency" : {"_value" : "Denton and Reddish"} , "tablingMemberPrinted" : [{"_value" : "Andrew Gwynne"} ], "uin" : "38833"} , {"_about" : "http://data.parliament.uk/resources/431742", "AnsweringBody" : [{"_value" : "Department of Health"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/431742/answer", "answerText" : {"_value" : "

NHS England was formed in April 2013.<\/p>

The table below shows actual expenditure by clinical commissioning groups (CCGs) on mental health in 2013/14 and 2014/15 and forecast spend in 2015/16. This does not include spending on mental health services directly commissioned by NHS England.<\/p>

Total actual expenditure by on mental health by CCGs across all providers for 2013/14 and 2014/15 and the total forecast expenditure for 2015/16<\/p>

2013/14 actual spend (£ billion <\/ins>million<\/del>)<\/p><\/td>

2014/15 actual spend (£ billion<\/ins>million<\/del>)<\/p><\/td>

2015/16 forecast spend (£ billion <\/ins>million<\/del>)<\/p><\/td><\/tr>

9.6<\/p><\/td>

10.1<\/p><\/td>

10.6<\/p><\/td><\/tr><\/tbody><\/table>

Source:<\/em> NHS England<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4020", "label" : {"_value" : "Biography information for George Freeman"} } , "answeringMemberConstituency" : {"_value" : "Mid Norfolk"} , "answeringMemberPrinted" : {"_value" : "George Freeman"} , "dateOfAnswer" : {"_value" : "2015-11-26", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "true", "_datatype" : "boolean"} , "previousAnswerVersion" : {"_about" : "http://data.parliament.uk/resources/431742/answer/previousversion/32352", "answeringMember" : {"_about" : "http://data.parliament.uk/members/4020", "label" : {"_value" : "Biography information for George Freeman"} } , "answeringMemberConstituency" : {"_value" : "Mid Norfolk"} , "answeringMemberPrinted" : {"_value" : "George Freeman"} } , "questionFirstAnswered" : [{"_value" : "2015-11-26T16:25:03.7Z", "_datatype" : "dateTime"} ], "questionFirstMinisteriallyCorrected" : [{"_value" : "2015-12-02T14:16:07.33Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health"} , "answeringDeptSortName" : {"_value" : "Health"} , "date" : {"_value" : "2015-11-23", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Mental Health Services: Per Capita Costs"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Health, how much NHS England spent per head on mental health in each year since 2008.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/3932", "label" : {"_value" : "Biography information for Dr Dan Poulter"} } , "tablingMemberConstituency" : {"_value" : "Central Suffolk and North Ipswich"} , "tablingMemberPrinted" : [{"_value" : "Dr Poulter"} ], "uin" : "17404"} , {"_about" : "http://data.parliament.uk/resources/224735", "AnsweringBody" : [{"_value" : "Department of Health"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/224735/answer", "answerText" : {"_value" : "

Clinical commissioning group (CCG) funding has not been decided beyond 2015/16. Notified revenue allocations and per capita allocations for Cumbria CCG are:<\/p>

<\/p>

<\/p>

<\/p>

Year<\/p><\/td>

Allocation £000<\/p><\/td>

Per capita £<\/p><\/td><\/tr>

2013/14<\/p><\/td>

692,122<\/del><\/p>

663,133<\/ins><\/p><\/td>

1,330<\/del><\/p>

1,274<\/ins><\/p><\/td><\/tr>

2014/15<\/p><\/td>

677,324<\/p><\/td>

1,299<\/p><\/td><\/tr>

2015/16<\/p><\/td>

685,654<\/p><\/td>

1,313<\/p><\/td><\/tr><\/tbody><\/table>

<\/p>

<\/p>

<\/p>

These figures exclude running cost and Better Care Fund allocations.<\/p>

<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4020", "label" : {"_value" : "Biography information for George Freeman"} } , "answeringMemberConstituency" : {"_value" : "Mid Norfolk"} , "answeringMemberPrinted" : {"_value" : "George Freeman"} , "dateOfAnswer" : {"_value" : "2015-03-06", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "true", "_datatype" : "boolean"} , "previousAnswerVersion" : {"_about" : "http://data.parliament.uk/resources/224735/answer/previousversion/48371", "answeringMember" : {"_about" : "http://data.parliament.uk/members/4020", "label" : {"_value" : "Biography information for George Freeman"} } , "answeringMemberConstituency" : {"_value" : "Mid Norfolk"} , "answeringMemberPrinted" : {"_value" : "George Freeman"} } , "questionFirstAnswered" : [{"_value" : "2015-03-06T14:39:07.327Z", "_datatype" : "dateTime"} ], "questionFirstMinisteriallyCorrected" : [{"_value" : "2015-03-19T18:02:16.817Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health"} , "answeringDeptSortName" : {"_value" : "Health"} , "date" : {"_value" : "2015-03-03", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Clinical Commissioning Groups: Cumbria"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Health, what funding (a) in total and (b) per capita has been allocated for Cumbria Clinical Commissioning Group for each year from 2013-14 to 2019-20.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/1503", "label" : {"_value" : "Biography information for Mr Jamie Reed"} } , "tablingMemberConstituency" : {"_value" : "Copeland"} , "tablingMemberPrinted" : [{"_value" : "Mr Jamie Reed"} ], "uin" : "226114"} , {"_about" : "http://data.parliament.uk/resources/100885", "AnsweringBody" : [{"_value" : "Department of Health"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/100885/answer", "answerText" : {"_value" : "

The following table shows estimated expenditure on research on asthma, motor neurone disease (MND) and osteoporosis by the Medical Research Council, other Research Councils and Innovate UK, and by the National Institute for Health (NIHR) through its research programmes, research centres and units, and research fellowships.<\/p>

<\/p>

<\/p>

<\/p>

£ million<\/em><\/p>

<\/p>
<\/td>

2009-10<\/p><\/td>

2010-11<\/p><\/td>

2011-12<\/p><\/td>

2012-13<\/p><\/td>

2013-14<\/p><\/td><\/tr>

Asthma<\/p><\/td><\/tr>

Medical Research Council<\/p><\/td>

22.2 <\/del>6.6<\/ins><\/p><\/td>

17.5 <\/del>5.3<\/ins><\/p><\/td>

17.2<\/del> 4.5<\/ins><\/p><\/td>

19.4<\/del> 3.6<\/ins><\/p><\/td>

18.8<\/del> 5.4<\/ins><\/p><\/td><\/tr>

Other Research Councils and Innovate UK<\/p><\/td>

0.0<\/p><\/td>

0.1<\/p><\/td>

0.3<\/p><\/td>

1.5<\/p><\/td>

0.8<\/p><\/td><\/tr>

National Institute for Health Research<\/p><\/td>

2.6<\/p><\/td>

3.4<\/p><\/td>

2.4<\/p><\/td>

3.4<\/p><\/td>

3.8<\/p><\/td><\/tr>

Total<\/p><\/td>

24.8<\/del> 9.2<\/ins><\/p><\/td>

21.0<\/del> 8.8<\/ins><\/p><\/td>

19.9<\/del> 7.2<\/ins><\/p><\/td>

24.3 <\/del>8.5<\/ins><\/p><\/td>

23.4<\/del> 10.0<\/ins><\/p><\/td><\/tr>

Motor Neurone Research<\/p><\/td><\/tr>

Medical Research Council<\/p><\/td>

7.0<\/p><\/td>

7.5<\/p><\/td>

4.2<\/p><\/td>

4.1<\/p><\/td>

3.6<\/p><\/td><\/tr>

Other Research Councils and Innovate UK<\/p><\/td>

0.2<\/p><\/td>

0.2<\/p><\/td>

0.4<\/p><\/td>

0.7<\/p><\/td>

1.0<\/p><\/td><\/tr>

National Institute for Health Research<\/p><\/td>

0.1<\/p><\/td>

0.1<\/p><\/td>

0.4<\/p><\/td>

0.7<\/p><\/td>

0.5<\/p><\/td><\/tr>

Total<\/p><\/td>

7.3<\/p><\/td>

7.8<\/p><\/td>

5.0<\/p><\/td>

5.5<\/p><\/td>

5.1<\/p><\/td><\/tr>

Osteoporosis<\/p><\/td><\/tr>

Medical Research Council<\/p><\/td>

6.2<\/p><\/td>

5.4<\/p><\/td>

5.1<\/p><\/td>

4.6<\/p><\/td>

5.9<\/p><\/td><\/tr>

Other Research Councils and Innovate UK<\/p><\/td>

0.0<\/p><\/td>

0.0<\/p><\/td>

0.1<\/p><\/td>

0.4<\/p><\/td>

1.0<\/p><\/td><\/tr>

National Institute for Health Research<\/p><\/td>

0.3<\/p><\/td>

0.7<\/p><\/td>

0.8<\/p><\/td>

1.3<\/p><\/td>

1.8<\/p><\/td><\/tr>

Total<\/p><\/td>

6.5<\/p><\/td>

6.1<\/p><\/td>

6.0<\/p><\/td>

6.3<\/p><\/td>

8.7<\/p><\/td><\/tr><\/tbody><\/table>

<\/p>

<\/p>

<\/p>

The figures shown for asthma exclude research into air pollution and potential effects on health outcomes including asthma.<\/p>

<\/p>

<\/p>

<\/p>

Total spend by the NIHR on asthma, MND and osteoporosis is higher than the figures shown because expenditure by the NIHR Clinical Research Network (CRN) on these diseases cannot be disaggregated from total CRN expenditure. NIHR expenditure relating to development of new drugs for asthma, MND and osteroporosis occurs primarily through NIHR research infrastructure including the CRN and cannot be disaggregated from total expenditure.<\/p>

<\/p>

<\/p>

<\/p>

Information on MRC expenditure into the development of new drugs for asthma, MND or osteoporosis is not available.<\/p>

<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4020", "label" : {"_value" : "Biography information for George Freeman"} } , "answeringMemberConstituency" : {"_value" : "Mid Norfolk"} , "answeringMemberPrinted" : {"_value" : "George Freeman"} , "dateOfAnswer" : {"_value" : "2014-10-29", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "true", "_datatype" : "boolean"} , "previousAnswerVersion" : {"_about" : "http://data.parliament.uk/resources/100885/answer/previousversion/25123", "answeringMember" : {"_about" : "http://data.parliament.uk/members/4020", "label" : {"_value" : "Biography information for George Freeman"} } , "answeringMemberConstituency" : {"_value" : "Mid Norfolk"} , "answeringMemberPrinted" : {"_value" : "George Freeman"} } , "questionFirstAnswered" : [{"_value" : "2014-10-29T17:12:29.113Z", "_datatype" : "dateTime"} ], "questionFirstMinisteriallyCorrected" : [{"_value" : "2014-11-13T10:22:56.0372213Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health"} , "answeringDeptSortName" : {"_value" : "Health"} , "date" : {"_value" : "2014-10-24", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Asthma: Drugs"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Health, how much the Government has spent on the development of new drugs to treat the symptoms of asthma in each of the last five years.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4026", "label" : {"_value" : "Biography information for Liz Kendall"} } , "tablingMemberConstituency" : {"_value" : "Leicester West"} , "tablingMemberPrinted" : [{"_value" : "Liz Kendall"} ], "uin" : "211885"} , {"_about" : "http://data.parliament.uk/resources/100887", "AnsweringBody" : [{"_value" : "Department of Health"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/100887/answer", "answerText" : {"_value" : "

The following table shows estimated expenditure on research on asthma, motor neurone disease (MND) and osteoporosis by the Medical Research Council, other Research Councils and Innovate UK, and by the National Institute for Health (NIHR) through its research programmes, research centres and units, and research fellowships.<\/p>

<\/p>

<\/p>

<\/p>

£ million<\/em><\/p>

<\/p>
<\/td>

2009-10<\/p><\/td>

2010-11<\/p><\/td>

2011-12<\/p><\/td>

2012-13<\/p><\/td>

2013-14<\/p><\/td><\/tr>

Asthma<\/p><\/td><\/tr>

Medical Research Council<\/p><\/td>

22.2 <\/del>6.6<\/ins><\/p><\/td>

17.5 <\/del>5.3<\/ins><\/p><\/td>

17.2<\/del> 4.5<\/ins><\/p><\/td>

19.4<\/del> 3.6<\/ins><\/p><\/td>

18.8<\/del> 5.4<\/ins><\/p><\/td><\/tr>

Other Research Councils and Innovate UK<\/p><\/td>

0.0<\/p><\/td>

0.1<\/p><\/td>

0.3<\/p><\/td>

1.5<\/p><\/td>

0.8<\/p><\/td><\/tr>

National Institute for Health Research<\/p><\/td>

2.6<\/p><\/td>

3.4<\/p><\/td>

2.4<\/p><\/td>

3.4<\/p><\/td>

3.8<\/p><\/td><\/tr>

Total<\/p><\/td>

24.8<\/del> 9.2<\/ins><\/p><\/td>

21.0<\/del> 8.8<\/ins><\/p><\/td>

19.9<\/del> 7.2<\/ins><\/p><\/td>

24.3 <\/del>8.5<\/ins><\/p><\/td>

23.4<\/del> 10.0<\/ins><\/p><\/td><\/tr>

Motor Neurone Research<\/p><\/td><\/tr>

Medical Research Council<\/p><\/td>

7.0<\/p><\/td>

7.5<\/p><\/td>

4.2<\/p><\/td>

4.1<\/p><\/td>

3.6<\/p><\/td><\/tr>

Other Research Councils and Innovate UK<\/p><\/td>

0.2<\/p><\/td>

0.2<\/p><\/td>

0.4<\/p><\/td>

0.7<\/p><\/td>

1.0<\/p><\/td><\/tr>

National Institute for Health Research<\/p><\/td>

0.1<\/p><\/td>

0.1<\/p><\/td>

0.4<\/p><\/td>

0.7<\/p><\/td>

0.5<\/p><\/td><\/tr>

Total<\/p><\/td>

7.3<\/p><\/td>

7.8<\/p><\/td>

5.0<\/p><\/td>

5.5<\/p><\/td>

5.1<\/p><\/td><\/tr>

Osteoporosis<\/p><\/td><\/tr>

Medical Research Council<\/p><\/td>

6.2<\/p><\/td>

5.4<\/p><\/td>

5.1<\/p><\/td>

4.6<\/p><\/td>

5.9<\/p><\/td><\/tr>

Other Research Councils and Innovate UK<\/p><\/td>

0.0<\/p><\/td>

0.0<\/p><\/td>

0.1<\/p><\/td>

0.4<\/p><\/td>

1.0<\/p><\/td><\/tr>

National Institute for Health Research<\/p><\/td>

0.3<\/p><\/td>

0.7<\/p><\/td>

0.8<\/p><\/td>

1.3<\/p><\/td>

1.8<\/p><\/td><\/tr>

Total<\/p><\/td>

6.5<\/p><\/td>

6.1<\/p><\/td>

6.0<\/p><\/td>

6.3<\/p><\/td>

8.7<\/p><\/td><\/tr><\/tbody><\/table>

<\/p>

<\/p>

<\/p>

The figures shown for asthma exclude research into air pollution and potential effects on health outcomes including asthma.<\/p>

<\/p>

<\/p>

<\/p>

Total spend by the NIHR on asthma, MND and osteoporosis is higher than the figures shown because expenditure by the NIHR Clinical Research Network (CRN) on these diseases cannot be disaggregated from total CRN expenditure. NIHR expenditure relating to development of new drugs for asthma, MND and osteroporosis occurs primarily through NIHR research infrastructure including the CRN and cannot be disaggregated from total expenditure.<\/p>

<\/p>

<\/p>

<\/p>

Information on MRC expenditure into the development of new drugs for asthma, MND or osteoporosis is not available.<\/p>

<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4020", "label" : {"_value" : "Biography information for George Freeman"} } , "answeringMemberConstituency" : {"_value" : "Mid Norfolk"} , "answeringMemberPrinted" : {"_value" : "George Freeman"} , "dateOfAnswer" : {"_value" : "2014-10-29", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "true", "_datatype" : "boolean"} , "previousAnswerVersion" : {"_about" : "http://data.parliament.uk/resources/100887/answer/previousversion/25123", "answeringMember" : {"_about" : "http://data.parliament.uk/members/4020", "label" : {"_value" : "Biography information for George Freeman"} } , "answeringMemberConstituency" : {"_value" : "Mid Norfolk"} , "answeringMemberPrinted" : {"_value" : "George Freeman"} } , "questionFirstAnswered" : [{"_value" : "2014-10-29T17:12:28.3318918Z", "_datatype" : "dateTime"} ], "questionFirstMinisteriallyCorrected" : [{"_value" : "2014-11-13T10:22:56.0372213Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health"} , "answeringDeptSortName" : {"_value" : "Health"} , "date" : {"_value" : "2014-10-24", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Asthma"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Health, how much public funding was allocated to research into asthma in each of the last five years.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4026", "label" : {"_value" : "Biography information for Liz Kendall"} } , "tablingMemberConstituency" : {"_value" : "Leicester West"} , "tablingMemberPrinted" : [{"_value" : "Liz Kendall"} ], "uin" : "211918"} , {"_about" : "http://data.parliament.uk/resources/100721", "AnsweringBody" : [{"_value" : "Department of Health"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/100721/answer", "answerText" : {"_value" : "

The following table shows estimated expenditure on research on asthma, motor neurone disease (MND) and osteoporosis by the Medical Research Council, other Research Councils and Innovate UK, and by the National Institute for Health (NIHR) through its research programmes, research centres and units, and research fellowships.<\/p>

<\/p>

<\/p>

<\/p>

£ million<\/em><\/p>

<\/p>
<\/td>

2009-10<\/p><\/td>

2010-11<\/p><\/td>

2011-12<\/p><\/td>

2012-13<\/p><\/td>

2013-14<\/p><\/td><\/tr>

Asthma<\/p><\/td><\/tr>

Medical Research Council<\/p><\/td>

22.2 <\/del>6.6<\/ins><\/p><\/td>

17.5 <\/del>5.3<\/ins><\/p><\/td>

17.2<\/del> 4.5<\/ins><\/p><\/td>

19.4<\/del> 3.6<\/ins><\/p><\/td>

18.8<\/del> 5.4<\/ins><\/p><\/td><\/tr>

Other Research Councils and Innovate UK<\/p><\/td>

0.0<\/p><\/td>

0.1<\/p><\/td>

0.3<\/p><\/td>

1.5<\/p><\/td>

0.8<\/p><\/td><\/tr>

National Institute for Health Research<\/p><\/td>

2.6<\/p><\/td>

3.4<\/p><\/td>

2.4<\/p><\/td>

3.4<\/p><\/td>

3.8<\/p><\/td><\/tr>

Total<\/p><\/td>

24.8<\/del> 9.2<\/ins><\/p><\/td>

21.0<\/del> 8.8<\/ins><\/p><\/td>

19.9<\/del> 7.2<\/ins><\/p><\/td>

24.3 <\/del>8.5<\/ins><\/p><\/td>

23.4<\/del> 10.0<\/ins><\/p><\/td><\/tr>

Motor Neurone Research<\/p><\/td><\/tr>

Medical Research Council<\/p><\/td>

7.0<\/p><\/td>

7.5<\/p><\/td>

4.2<\/p><\/td>

4.1<\/p><\/td>

3.6<\/p><\/td><\/tr>

Other Research Councils and Innovate UK<\/p><\/td>

0.2<\/p><\/td>

0.2<\/p><\/td>

0.4<\/p><\/td>

0.7<\/p><\/td>

1.0<\/p><\/td><\/tr>

National Institute for Health Research<\/p><\/td>

0.1<\/p><\/td>

0.1<\/p><\/td>

0.4<\/p><\/td>

0.7<\/p><\/td>

0.5<\/p><\/td><\/tr>

Total<\/p><\/td>

7.3<\/p><\/td>

7.8<\/p><\/td>

5.0<\/p><\/td>

5.5<\/p><\/td>

5.1<\/p><\/td><\/tr>

Osteoporosis<\/p><\/td><\/tr>

Medical Research Council<\/p><\/td>

6.2<\/p><\/td>

5.4<\/p><\/td>

5.1<\/p><\/td>

4.6<\/p><\/td>

5.9<\/p><\/td><\/tr>

Other Research Councils and Innovate UK<\/p><\/td>

0.0<\/p><\/td>

0.0<\/p><\/td>

0.1<\/p><\/td>

0.4<\/p><\/td>

1.0<\/p><\/td><\/tr>

National Institute for Health Research<\/p><\/td>

0.3<\/p><\/td>

0.7<\/p><\/td>

0.8<\/p><\/td>

1.3<\/p><\/td>

1.8<\/p><\/td><\/tr>

Total<\/p><\/td>

6.5<\/p><\/td>

6.1<\/p><\/td>

6.0<\/p><\/td>

6.3<\/p><\/td>

8.7<\/p><\/td><\/tr><\/tbody><\/table>

<\/p>

<\/p>

<\/p>

The figures shown for asthma exclude research into air pollution and potential effects on health outcomes including asthma.<\/p>

<\/p>

<\/p>

<\/p>

Total spend by the NIHR on asthma, MND and osteoporosis is higher than the figures shown because expenditure by the NIHR Clinical Research Network (CRN) on these diseases cannot be disaggregated from total CRN expenditure. NIHR expenditure relating to development of new drugs for asthma, MND and osteroporosis occurs primarily through NIHR research infrastructure including the CRN and cannot be disaggregated from total expenditure.<\/p>

<\/p>

<\/p>

<\/p>

Information on MRC expenditure into the development of new drugs for asthma, MND or osteoporosis is not available.<\/p>

<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4020", "label" : {"_value" : "Biography information for George Freeman"} } , "answeringMemberConstituency" : {"_value" : "Mid Norfolk"} , "answeringMemberPrinted" : {"_value" : "George Freeman"} , "dateOfAnswer" : {"_value" : "2014-10-29", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "true", "_datatype" : "boolean"} , "previousAnswerVersion" : {"_about" : "http://data.parliament.uk/resources/100721/answer/previousversion/25123", "answeringMember" : {"_about" : "http://data.parliament.uk/members/4020", "label" : {"_value" : "Biography information for George Freeman"} } , "answeringMemberConstituency" : {"_value" : "Mid Norfolk"} , "answeringMemberPrinted" : {"_value" : "George Freeman"} } , "questionFirstAnswered" : [{"_value" : "2014-10-29T17:12:28.3318918Z", "_datatype" : "dateTime"} ], "questionFirstMinisteriallyCorrected" : [{"_value" : "2014-11-13T10:22:56.0372213Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health"} , "answeringDeptSortName" : {"_value" : "Health"} , "date" : {"_value" : "2014-10-23", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Osteoporosis"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Health, how much from the publich purse has been spent on research into osteoporosis in each of the last five years.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4026", "label" : {"_value" : "Biography information for Liz Kendall"} } , "tablingMemberConstituency" : {"_value" : "Leicester West"} , "tablingMemberPrinted" : [{"_value" : "Liz Kendall"} ], "uin" : "211732"} , {"_about" : "http://data.parliament.uk/resources/100723", "AnsweringBody" : [{"_value" : "Department of Health"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/100723/answer", "answerText" : {"_value" : "

The following table shows estimated expenditure on research on asthma, motor neurone disease (MND) and osteoporosis by the Medical Research Council, other Research Councils and Innovate UK, and by the National Institute for Health (NIHR) through its research programmes, research centres and units, and research fellowships.<\/p>

<\/p>

<\/p>

<\/p>

£ million<\/em><\/p>

<\/p>
<\/td>

2009-10<\/p><\/td>

2010-11<\/p><\/td>

2011-12<\/p><\/td>

2012-13<\/p><\/td>

2013-14<\/p><\/td><\/tr>

Asthma<\/p><\/td><\/tr>

Medical Research Council<\/p><\/td>

22.2 <\/del>6.6<\/ins><\/p><\/td>

17.5 <\/del>5.3<\/ins><\/p><\/td>

17.2<\/del> 4.5<\/ins><\/p><\/td>

19.4<\/del> 3.6<\/ins><\/p><\/td>

18.8<\/del> 5.4<\/ins><\/p><\/td><\/tr>

Other Research Councils and Innovate UK<\/p><\/td>

0.0<\/p><\/td>

0.1<\/p><\/td>

0.3<\/p><\/td>

1.5<\/p><\/td>

0.8<\/p><\/td><\/tr>

National Institute for Health Research<\/p><\/td>

2.6<\/p><\/td>

3.4<\/p><\/td>

2.4<\/p><\/td>

3.4<\/p><\/td>

3.8<\/p><\/td><\/tr>

Total<\/p><\/td>

24.8<\/del> 9.2<\/ins><\/p><\/td>

21.0<\/del> 8.8<\/ins><\/p><\/td>

19.9<\/del> 7.2<\/ins><\/p><\/td>

24.3 <\/del>8.5<\/ins><\/p><\/td>

23.4<\/del> 10.0<\/ins><\/p><\/td><\/tr>

Motor Neurone Research<\/p><\/td><\/tr>

Medical Research Council<\/p><\/td>

7.0<\/p><\/td>

7.5<\/p><\/td>

4.2<\/p><\/td>

4.1<\/p><\/td>

3.6<\/p><\/td><\/tr>

Other Research Councils and Innovate UK<\/p><\/td>

0.2<\/p><\/td>

0.2<\/p><\/td>

0.4<\/p><\/td>

0.7<\/p><\/td>

1.0<\/p><\/td><\/tr>

National Institute for Health Research<\/p><\/td>

0.1<\/p><\/td>

0.1<\/p><\/td>

0.4<\/p><\/td>

0.7<\/p><\/td>

0.5<\/p><\/td><\/tr>

Total<\/p><\/td>

7.3<\/p><\/td>

7.8<\/p><\/td>

5.0<\/p><\/td>

5.5<\/p><\/td>

5.1<\/p><\/td><\/tr>

Osteoporosis<\/p><\/td><\/tr>

Medical Research Council<\/p><\/td>

6.2<\/p><\/td>

5.4<\/p><\/td>

5.1<\/p><\/td>

4.6<\/p><\/td>

5.9<\/p><\/td><\/tr>

Other Research Councils and Innovate UK<\/p><\/td>

0.0<\/p><\/td>

0.0<\/p><\/td>

0.1<\/p><\/td>

0.4<\/p><\/td>

1.0<\/p><\/td><\/tr>

National Institute for Health Research<\/p><\/td>

0.3<\/p><\/td>

0.7<\/p><\/td>

0.8<\/p><\/td>

1.3<\/p><\/td>

1.8<\/p><\/td><\/tr>

Total<\/p><\/td>

6.5<\/p><\/td>

6.1<\/p><\/td>

6.0<\/p><\/td>

6.3<\/p><\/td>

8.7<\/p><\/td><\/tr><\/tbody><\/table>

<\/p>

<\/p>

<\/p>

The figures shown for asthma exclude research into air pollution and potential effects on health outcomes including asthma.<\/p>

<\/p>

<\/p>

<\/p>

Total spend by the NIHR on asthma, MND and osteoporosis is higher than the figures shown because expenditure by the NIHR Clinical Research Network (CRN) on these diseases cannot be disaggregated from total CRN expenditure. NIHR expenditure relating to development of new drugs for asthma, MND and osteroporosis occurs primarily through NIHR research infrastructure including the CRN and cannot be disaggregated from total expenditure.<\/p>

<\/p>

<\/p>

<\/p>

Information on MRC expenditure into the development of new drugs for asthma, MND or osteoporosis is not available.<\/p>

<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4020", "label" : {"_value" : "Biography information for George Freeman"} } , "answeringMemberConstituency" : {"_value" : "Mid Norfolk"} , "answeringMemberPrinted" : {"_value" : "George Freeman"} , "dateOfAnswer" : {"_value" : "2014-10-29", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "true", "_datatype" : "boolean"} , "previousAnswerVersion" : {"_about" : "http://data.parliament.uk/resources/100723/answer/previousversion/25123", "answeringMember" : {"_about" : "http://data.parliament.uk/members/4020", "label" : {"_value" : "Biography information for George Freeman"} } , "answeringMemberConstituency" : {"_value" : "Mid Norfolk"} , "answeringMemberPrinted" : {"_value" : "George Freeman"} } , "questionFirstAnswered" : [{"_value" : "2014-10-29T17:12:28.3318918Z", "_datatype" : "dateTime"} ], "questionFirstMinisteriallyCorrected" : [{"_value" : "2014-11-13T10:22:56.0372213Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health"} , "answeringDeptSortName" : {"_value" : "Health"} , "date" : {"_value" : "2014-10-23", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Motor Neurone Disease: Drugs"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Health, how much from the public purse has been spent on the development of new drugs to prevent or treat symptoms of motore neurone disease in each of the last five years.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4026", "label" : {"_value" : "Biography information for Liz Kendall"} } , "tablingMemberConstituency" : {"_value" : "Leicester West"} , "tablingMemberPrinted" : [{"_value" : "Liz Kendall"} ], "uin" : "211734"} , {"_about" : "http://data.parliament.uk/resources/100728", "AnsweringBody" : [{"_value" : "Department of Health"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/100728/answer", "answerText" : {"_value" : "

The following table shows estimated expenditure on research on asthma, motor neurone disease (MND) and osteoporosis by the Medical Research Council, other Research Councils and Innovate UK, and by the National Institute for Health (NIHR) through its research programmes, research centres and units, and research fellowships.<\/p>

<\/p>

<\/p>

<\/p>

£ million<\/em><\/p>

<\/p>
<\/td>

2009-10<\/p><\/td>

2010-11<\/p><\/td>

2011-12<\/p><\/td>

2012-13<\/p><\/td>

2013-14<\/p><\/td><\/tr>

Asthma<\/p><\/td><\/tr>

Medical Research Council<\/p><\/td>

22.2 <\/del>6.6<\/ins><\/p><\/td>

17.5 <\/del>5.3<\/ins><\/p><\/td>

17.2<\/del> 4.5<\/ins><\/p><\/td>

19.4<\/del> 3.6<\/ins><\/p><\/td>

18.8<\/del> 5.4<\/ins><\/p><\/td><\/tr>

Other Research Councils and Innovate UK<\/p><\/td>

0.0<\/p><\/td>

0.1<\/p><\/td>

0.3<\/p><\/td>

1.5<\/p><\/td>

0.8<\/p><\/td><\/tr>

National Institute for Health Research<\/p><\/td>

2.6<\/p><\/td>

3.4<\/p><\/td>

2.4<\/p><\/td>

3.4<\/p><\/td>

3.8<\/p><\/td><\/tr>

Total<\/p><\/td>

24.8<\/del> 9.2<\/ins><\/p><\/td>

21.0<\/del> 8.8<\/ins><\/p><\/td>

19.9<\/del> 7.2<\/ins><\/p><\/td>

24.3 <\/del>8.5<\/ins><\/p><\/td>

23.4<\/del> 10.0<\/ins><\/p><\/td><\/tr>

Motor Neurone Research<\/p><\/td><\/tr>

Medical Research Council<\/p><\/td>

7.0<\/p><\/td>

7.5<\/p><\/td>

4.2<\/p><\/td>

4.1<\/p><\/td>

3.6<\/p><\/td><\/tr>

Other Research Councils and Innovate UK<\/p><\/td>

0.2<\/p><\/td>

0.2<\/p><\/td>

0.4<\/p><\/td>

0.7<\/p><\/td>

1.0<\/p><\/td><\/tr>

National Institute for Health Research<\/p><\/td>

0.1<\/p><\/td>

0.1<\/p><\/td>

0.4<\/p><\/td>

0.7<\/p><\/td>

0.5<\/p><\/td><\/tr>

Total<\/p><\/td>

7.3<\/p><\/td>

7.8<\/p><\/td>

5.0<\/p><\/td>

5.5<\/p><\/td>

5.1<\/p><\/td><\/tr>

Osteoporosis<\/p><\/td><\/tr>

Medical Research Council<\/p><\/td>

6.2<\/p><\/td>

5.4<\/p><\/td>

5.1<\/p><\/td>

4.6<\/p><\/td>

5.9<\/p><\/td><\/tr>

Other Research Councils and Innovate UK<\/p><\/td>

0.0<\/p><\/td>

0.0<\/p><\/td>

0.1<\/p><\/td>

0.4<\/p><\/td>

1.0<\/p><\/td><\/tr>

National Institute for Health Research<\/p><\/td>

0.3<\/p><\/td>

0.7<\/p><\/td>

0.8<\/p><\/td>

1.3<\/p><\/td>

1.8<\/p><\/td><\/tr>

Total<\/p><\/td>

6.5<\/p><\/td>

6.1<\/p><\/td>

6.0<\/p><\/td>

6.3<\/p><\/td>

8.7<\/p><\/td><\/tr><\/tbody><\/table>

<\/p>

<\/p>

<\/p>

The figures shown for asthma exclude research into air pollution and potential effects on health outcomes including asthma.<\/p>

<\/p>

<\/p>

<\/p>

Total spend by the NIHR on asthma, MND and osteoporosis is higher than the figures shown because expenditure by the NIHR Clinical Research Network (CRN) on these diseases cannot be disaggregated from total CRN expenditure. NIHR expenditure relating to development of new drugs for asthma, MND and osteroporosis occurs primarily through NIHR research infrastructure including the CRN and cannot be disaggregated from total expenditure.<\/p>

<\/p>

<\/p>

<\/p>

Information on MRC expenditure into the development of new drugs for asthma, MND or osteoporosis is not available.<\/p>

<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4020", "label" : {"_value" : "Biography information for George Freeman"} } , "answeringMemberConstituency" : {"_value" : "Mid Norfolk"} , "answeringMemberPrinted" : {"_value" : "George Freeman"} , "dateOfAnswer" : {"_value" : "2014-10-29", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "true", "_datatype" : "boolean"} , "previousAnswerVersion" : {"_about" : "http://data.parliament.uk/resources/100728/answer/previousversion/25123", "answeringMember" : {"_about" : "http://data.parliament.uk/members/4020", "label" : {"_value" : "Biography information for George Freeman"} } , "answeringMemberConstituency" : {"_value" : "Mid Norfolk"} , "answeringMemberPrinted" : {"_value" : "George Freeman"} } , "questionFirstAnswered" : [{"_value" : "2014-10-29T17:12:28.3318918Z", "_datatype" : "dateTime"} ], "questionFirstMinisteriallyCorrected" : [{"_value" : "2014-11-13T10:22:56.0372213Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health"} , "answeringDeptSortName" : {"_value" : "Health"} , "date" : {"_value" : "2014-10-23", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Motor Neurone Disease"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Health, how much from the public purse has been spent on research into motor neurone disease in each of the last five years.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4026", "label" : {"_value" : "Biography information for Liz Kendall"} } , "tablingMemberConstituency" : {"_value" : "Leicester West"} , "tablingMemberPrinted" : [{"_value" : "Liz Kendall"} ], "uin" : "211730"} , {"_about" : "http://data.parliament.uk/resources/100730", "AnsweringBody" : [{"_value" : "Department of Health"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/100730/answer", "answerText" : {"_value" : "

The following table shows estimated expenditure on research on asthma, motor neurone disease (MND) and osteoporosis by the Medical Research Council, other Research Councils and Innovate UK, and by the National Institute for Health (NIHR) through its research programmes, research centres and units, and research fellowships.<\/p>

<\/p>

<\/p>

<\/p>

£ million<\/em><\/p>

<\/p>
<\/td>

2009-10<\/p><\/td>

2010-11<\/p><\/td>

2011-12<\/p><\/td>

2012-13<\/p><\/td>

2013-14<\/p><\/td><\/tr>

Asthma<\/p><\/td><\/tr>

Medical Research Council<\/p><\/td>

22.2 <\/del>6.6<\/ins><\/p><\/td>

17.5 <\/del>5.3<\/ins><\/p><\/td>

17.2<\/del> 4.5<\/ins><\/p><\/td>

19.4<\/del> 3.6<\/ins><\/p><\/td>

18.8<\/del> 5.4<\/ins><\/p><\/td><\/tr>

Other Research Councils and Innovate UK<\/p><\/td>

0.0<\/p><\/td>

0.1<\/p><\/td>

0.3<\/p><\/td>

1.5<\/p><\/td>

0.8<\/p><\/td><\/tr>

National Institute for Health Research<\/p><\/td>

2.6<\/p><\/td>

3.4<\/p><\/td>

2.4<\/p><\/td>

3.4<\/p><\/td>

3.8<\/p><\/td><\/tr>

Total<\/p><\/td>

24.8<\/del> 9.2<\/ins><\/p><\/td>

21.0<\/del> 8.8<\/ins><\/p><\/td>

19.9<\/del> 7.2<\/ins><\/p><\/td>

24.3 <\/del>8.5<\/ins><\/p><\/td>

23.4<\/del> 10.0<\/ins><\/p><\/td><\/tr>

Motor Neurone Research<\/p><\/td><\/tr>

Medical Research Council<\/p><\/td>

7.0<\/p><\/td>

7.5<\/p><\/td>

4.2<\/p><\/td>

4.1<\/p><\/td>

3.6<\/p><\/td><\/tr>

Other Research Councils and Innovate UK<\/p><\/td>

0.2<\/p><\/td>

0.2<\/p><\/td>

0.4<\/p><\/td>

0.7<\/p><\/td>

1.0<\/p><\/td><\/tr>

National Institute for Health Research<\/p><\/td>

0.1<\/p><\/td>

0.1<\/p><\/td>

0.4<\/p><\/td>

0.7<\/p><\/td>

0.5<\/p><\/td><\/tr>

Total<\/p><\/td>

7.3<\/p><\/td>

7.8<\/p><\/td>

5.0<\/p><\/td>

5.5<\/p><\/td>

5.1<\/p><\/td><\/tr>

Osteoporosis<\/p><\/td><\/tr>

Medical Research Council<\/p><\/td>

6.2<\/p><\/td>

5.4<\/p><\/td>

5.1<\/p><\/td>

4.6<\/p><\/td>

5.9<\/p><\/td><\/tr>

Other Research Councils and Innovate UK<\/p><\/td>

0.0<\/p><\/td>

0.0<\/p><\/td>

0.1<\/p><\/td>

0.4<\/p><\/td>

1.0<\/p><\/td><\/tr>

National Institute for Health Research<\/p><\/td>

0.3<\/p><\/td>

0.7<\/p><\/td>

0.8<\/p><\/td>

1.3<\/p><\/td>

1.8<\/p><\/td><\/tr>

Total<\/p><\/td>

6.5<\/p><\/td>

6.1<\/p><\/td>

6.0<\/p><\/td>

6.3<\/p><\/td>

8.7<\/p><\/td><\/tr><\/tbody><\/table>

<\/p>

<\/p>

<\/p>

The figures shown for asthma exclude research into air pollution and potential effects on health outcomes including asthma.<\/p>

<\/p>

<\/p>

<\/p>

Total spend by the NIHR on asthma, MND and osteoporosis is higher than the figures shown because expenditure by the NIHR Clinical Research Network (CRN) on these diseases cannot be disaggregated from total CRN expenditure. NIHR expenditure relating to development of new drugs for asthma, MND and osteroporosis occurs primarily through NIHR research infrastructure including the CRN and cannot be disaggregated from total expenditure.<\/p>

<\/p>

<\/p>

<\/p>

Information on MRC expenditure into the development of new drugs for asthma, MND or osteoporosis is not available.<\/p>

<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4020", "label" : {"_value" : "Biography information for George Freeman"} } , "answeringMemberConstituency" : {"_value" : "Mid Norfolk"} , "answeringMemberPrinted" : {"_value" : "George Freeman"} , "dateOfAnswer" : {"_value" : "2014-10-29", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "true", "_datatype" : "boolean"} , "previousAnswerVersion" : {"_about" : "http://data.parliament.uk/resources/100730/answer/previousversion/25123", "answeringMember" : {"_about" : "http://data.parliament.uk/members/4020", "label" : {"_value" : "Biography information for George Freeman"} } , "answeringMemberConstituency" : {"_value" : "Mid Norfolk"} , "answeringMemberPrinted" : {"_value" : "George Freeman"} } , "questionFirstAnswered" : [{"_value" : "2014-10-29T17:12:28.3318918Z", "_datatype" : "dateTime"} ], "questionFirstMinisteriallyCorrected" : [{"_value" : "2014-11-13T10:22:56.0372213Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health"} , "answeringDeptSortName" : {"_value" : "Health"} , "date" : {"_value" : "2014-10-23", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Osteoporosis: Drugs"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Health, how much from the public purse has been spent on the development of new drugs to treat symptoms of osteoporosis in each of the last five years.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4026", "label" : {"_value" : "Biography information for Liz Kendall"} } , "tablingMemberConstituency" : {"_value" : "Leicester West"} , "tablingMemberPrinted" : [{"_value" : "Liz Kendall"} ], "uin" : "211735"} ], "itemsPerPage" : 10, "next" : "http://eldaddp.azurewebsites.net/answeredquestions.text?min-answer.dateOfAnswer=2014-10-28&_page=1&min-answer.questionFirstMinisteriallyCorrected.=2014-11-13T10%3A22%3A56.0372213Z&answer.answeringMemberConstituency=Mid+Norfolk", "page" : 0, "startIndex" : 1, "totalResults" : 10, "type" : ["http://purl.org/linked-data/api/vocab#ListEndpoint", "http://purl.org/linked-data/api/vocab#Page"]} }